Answers are grounded in this paper and cite their sources.
Background Lung adenocarcinoma (LUAD) is a common subtype of lung cancer with high morbidity and mortality. Absorption, Distribution, Metabolism, Excretion (ADME) genes play critical roles in drug pharmacokinetics and are implicated in cancer progression. The prognostic value of an ADME-related gene model in LUAD was explored in this study. Methods Clinical and RNA-seq datasets of LUAD patients were obtained from public databases, and 298 ADME genes were collected from the official site of Pharma-ADME. Clustering was performed using the “ConsensusClusterPlus” R package, and differentially expressed gene (DEG) analysis was conducted using limma and clusterProfiler packages. A risk model was constructed using the glmnet and survival packages, followed by validation through single sample gene set enrichment analysis (ssGSEA), quantitative Polymerase Chain Reaction (qPCR), and cell migration and invasion assays. Results Univariate Cox regression identified 22 prognostic ADME genes, which were used to cluster patients into C1 and C2 subtypes. These two subtypes exhibited distinct prognostic outcomes, with C2 having poor prognosis and inhibitory immune microenvironment. A total of 494 DEGs were screened and enriched to mitosis pathways. Subsequently, univariate Cox regression, LASSO Cox regression, and stepwise regression analyses were performed on these DEGs, leading to the development of a four-gene RiskScore model comprising ANLN, FAM83A, IRX5 , and RHOV . Using this model, we predicted that the overall survival was significantly worse in the high-risk group. The model genes were upregulated in tumor cells, particularly, ANLN affected the migration and invasion of LUAD cells. A nomogram was further established integrating the RiskScore. Notably, the low-risk group had higher immune infiltration, lower TIDE score, and more immunotherapy benefits. Conclusion The RiskScore model may serve as a potential tool to support prognostic assessment in LUAD, however, further validation in larger prospective cohorts is still warranted.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: